Dat'Aids Prevention

Study Overview
=================
Brief Summary
-----------------
DatAIDS prevention is a cohort study of HIV prevention in over 23 HIV sites in France including overseas, aiming to describe HIV prevention in every aspect including HIV screening, STI and hepatitis screening, post-exposure prophylaxis and pre-exposure prophylaxis

Official Title
-----------------
HIV Prevention in France : Dat'AIDS Prevention

Conditions
-----------------
HIV Prevention

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female over 18 years old, HIV negative Attending for : HIV screening Hepatitis screening STI screening / treatment Blood, body fluid or sexual exposure Post-exposure prophylaxis Pre-exposure prophylaxis Signed consent Exclusion Criteria: HIV-infection Refusal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients enrolled for HIV prevention in the cohort | Demographics, risk factors clinical and biological characteristics, treatment of patients enrolled for HIV prevention in the cohort | From date of enrollment, through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of persons enrolled for pre-exposure prophylaxis in the cohort | Demographics, risk factors clinical and biological characteristics, treatment of patients attending for pre-exposure prophylaxis in the cohort | From date of enrollment, through study completion, an average of 1 year | 
| Proportion of persons enrolled for post-exposure prophylaxis in the cohort | Demographics, risk factors clinical and biological characteristics, treatment of patients attending for post-exposure prophylaxis in the cohort | From date of enrollment, through study completion, an average of 1 year | 
| Proportion of persons enrolled for hepatitis screening in the cohort | Demographics, risk factors clinical and biological characteristics, treatment of patients attending for hepatitis screening in the cohort | From date of enrollment, through study completion, an average of 1 year | 
| Proportion of persons enrolled for pre-exposure prophylaxis in the cohort according to national French guidelines | Adequation between prevention practices and guidelines | From date of enrollment, through study completion, an average of 1 year | 
| Proportion of persons enrolled for post-exposure prophylaxis in the cohort according to national French guidelines | Adequation between prevention practices and guidelines | From date of enrollment, through study completion, an average of 1 year | 
| Incidence of STIs |  | From date of enrollment, through study completion, an average of 1 year | 
| Incidence of hepatitis |  | From date of enrollment, through study completion, an average of 1 year |